Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... and proapoptotic effects in combination with chemotherapy and trastuzumab Keywords: Acute Myeloid Leukemia, Clinical Trial Research, Enzymes, ...
2009 NOV 23 ... [F-18]FPEGMA, which was used to produce site-specifically F-18-labeled protein (F-18-trastuzumab-ThioFab) in 82 min with a total radiochemical yield of 13 +/- 3% and a specific activity ...
2009 NOV 16 ... for patients whose tumours exhibited a particularly high level of HER2 when Herceptin (trastuzumab) was added to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin). ...
2009 NOV 23 ... the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ...
2009 NOV 16 ... to receive 60% of the royalties from sales of Avastin=AE (Bevacizumab), Herceptin=AE (Trastuzumab), Lucentis=AE (Ranibizumab) and Xolair=AE (Omalizumab) and from sales of future ...
2009 NOV 9 ... to receive 60% of the royalties from sales of Avastin=AE (Bevacizumab), Herceptin=AE (Trastuzumab), Lucentis=AE (Ranibizumab) and Xolair=AE (Omalizumab) and from sales of future ...
2009 NOV 23 ... of their routine patient treatment protocols. Not all patients treated with trastuzumab (indication: breast cancer) and cetuximab (indication: metastatic colorectal cancer) ...
2009 NOV 23 ... "One of the recent advances in the treatment of breast cancer is trastuzumab. However, a major side effect of this medication is cardiomyopathy," scientists in the ...
2009 NOV 9 ... with Human Epidermal growth Receptor 2 (HER2)-positive Metastatic breast cancer (MBC), Trastuzumab has become the standard of care but previous studies have raised doubts about its ...
2009 NOV 23 ... receptor, < 35% are responsive to treatment with the HER2-disabling antibody, called trastuzumab (Herceptin)." "Despite those statistics, women diagnosed with breast ...
2009 NOV 10 ... and also includes the p110 beta isoform of PI3K. The PTEN-p85 association is enhanced by trastuzumab treatment and linked to a decline in AKT phosphorylation in some ERBB2-amplified breast ...
2009 NOV 9 ... (HR), the effects HR expression has oil clinical characteristics, including response to trastuzumab among HER2-positive breast cancer, has not been elucidated yet," scientists in Tel ...
2009 NOV 9 ... the efficacy and safety of neoadjuvant carboplatin and weekly paclitaxel +/- weekly trastuzumab in resectable and locally advanced breast cancer. Women with stages IIA to IIIB disease ...
2009 NOV 16 ... Seoul, South Korea, "We evaluated the efficacy and safety of weekly paclitaxel plus trastuzumab as first-line chemotherapy in women with HER2-overexpressing metastatic breast cancer ...
2009 NOV 9 ... evaluate the safety and immunogenicity of combination therapy consisting of concurrent trastuzumab and human epidermal growth factor receptor 2 (HER2)/neu-specific vaccination in patients ...
2009 NOV 16 ... for HER2-positive breast cancer patients, following primary surgery for their cancer, is Trastuzumab (Herceptin)--typically used in combination with chemotherapy. However, a new study by ...
2009 NOV 23 ... recurrence, and decreased survival compared to women with HER2-negative breast cancer. Trastuzumab is a monoclonal antibody that inhibits HER2 activity, making this compound an important ...
